Daré Bioscience, Inc.: Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate - pivotal Phase 3 contra ...
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated MilestonesOvaprene® hormone-free monthly ...